<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The health burden of <z:e sem="disease" ids="C0041234" disease_type="Disease or Syndrome" abbrv="">Chagas' disease</z:e> (resulting from <z:e sem="disease" ids="C0041234" disease_type="Disease or Syndrome" abbrv="">Trypanosoma cruzi infection</z:e>) in Latin America (estimated to outweigh that of <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> by 5-fold and affect 2-6 million people in Mexico alone) has motivated development of therapeutic vaccines to prevent <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> progression to severe disease </plain></SENT>
<SENT sid="1" pm="."><plain>Our economic model for a Chagas' therapeutic vaccine in Mexico suggests that a vaccine would be highly cost-effective and in many cases economically dominant (providing both cost savings and health benefits) throughout a range of protection durations, severe adverse event risk, and dosing regimens and would be most likely to provide a positive return on investment if the vaccine prevented (rather than delayed) the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
</text></document>